Area of research
Neurology · Cellular and Molecular Neuroscience
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Neuroscience and Neuropharmacology Research, and Genetic Neurodegenerative Diseases.
Toward a biological definition of neuronal and glial synucleinopathies
<i>LRRK2</i> -associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization
Alpha synuclein overexpression can drive microbiome dysbiosis in mice
T cell responses towards PINK1 and α-synuclein are elevated in prodromal Parkinson’s disease
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease
Foslevodopa/Foscarbidopa in Younger Patients Earlier Within Advanced Parkinson’s Disease: Post Hoc Analysis of a Randomized Trial
Connectomic-guided stereotactic radiosurgery thalamotomy for tremor: a patient-specific approach to enhance outcomes
Suppression of the JAK/STAT pathway inhibits neuroinflammation in the line 61-PFF mouse model of Parkinson’s disease
GLP-1, Parkinson’s Disease, and Neuroprotection
The emerging role of disease-associated microglia in Parkinson’s disease
Single molecule array measures of LRRK2 kinase activity in serum link Parkinson’s disease severity to peripheral inflammation
Levodopa infusion therapies for Parkinson disease
The Black and African American Connections to Parkinson’s Disease (BLAAC PD) study protocol
Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study
Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Brain and Systemic Inflammation in De Novo Parkinson's Disease
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
Population fraction of Parkinson’s disease attributable to preventable risk factors
Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson's disease continuum: Revelations from the MANAGE-PD validation cohort
Disease mechanisms as subtypes: Inflammation in Parkinson disease and related disorders
Connectomic Basis for Tremor Control in Stereotactic Radiosurgical Thalamotomy
Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures
Striatal Synaptic Dysfunction in Dystonia and Levodopa-Induced Dyskinesia
RORγt-Expressing Pathogenic CD4+ T Cells Cause Brain Inflammation during Chronic Colitis
Alpha-synuclein–mediated DNA damage, STING activation, and neuroinflammation in Parkinson’s disease
The emerging postural instability phenotype in idiopathic Parkinson disease
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up